ZIDA Sock for Overactive Bladder

Overseen By Louisa Keil

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: Medical University of South Carolina

Must be taking: OAB medications

Must not be taking: Neuromodulation therapies

Disqualifiers: Neurologic disease, Pelvic pathology, Pregnancy, others

Stay on Your Current Meds You can continue your current medications while participating

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

Duration: 12 weeks

20 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

Many people with overactive bladder (OAB) continue to experience symptoms despite pharmacologic treatment. This study evaluates the use of the ZIDA Control Sock, an FDA-cleared, noninvasive wearable device that delivers mild electrical stimulation near the ankle, as an adjunct to usual care. Adults with OAB-wet who remain symptomatic on stable medication will use the device at home once weekly for 12 weeks while continuing their prescribed therapy. The study collects clinical, patient-reported, and safety information during adjunctive device use.

Who Is on the Research Team?

Connie Wang, MD

Principal Investigator

Medical University of South Carolina

Eric Rovner, MD

Principal Investigator

Medical University of South Carolina

Are You a Good Fit for This Trial?

Inclusion Criteria

I have been diagnosed with overactive bladder with urgency incontinence.

I am able to fill out forms and attend follow-up appointments.

I am mentally able to understand and agree to the study on my own.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants use the ZIDA Control Sock at home once weekly for 12 weeks while continuing their prescribed pharmacologic therapy

12 weeks

Weekly home-based device use

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

• ZIDA Control Sock

How Is the Trial Designed?

Group I: ZIDA Add-On Therapy Experimental Treatment 1 Intervention

Participants will continue usual pharmacologic treatment for overactive bladder and will use the ZIDA Control Sock at home once weekly over the study treatment period. Device use is evaluated as an adjunct to standard care.

Who Is Running the Clinical Trial?

Medical University of South Carolina

Lead Sponsor

Trials

994

Recruited

7,408,000+

Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction

Collaborator

Trials

7

Recruited

360+

Medtronic

Industry Sponsor

Trials

627

Recruited

767,000+

Geoff Martha

Medtronic

Chief Executive Officer since 2020

Finance degree from Penn State University

Dr. Richard Kuntz

Medtronic

Chief Medical Officer since 2023

MD, MSc